Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia

PROVIDER: PRJNA997373 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25387644_1.fastq.gz	Fastqsanger.gz
	SRR25387644_2.fastq.gz	Fastqsanger.gz
	SRR25387645_1.fastq.gz	Fastqsanger.gz
	SRR25387645_2.fastq.gz	Fastqsanger.gz
	SRR25387646_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 84

Similar Datasets

Project description:Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia

| PRJNA1051602 | ENA

Project description:Measurable Residual FLT3-ITD before Allogeneic Transplant for Acute Myeloid Leukemia

| PRJNA1021545 | ENA

Project description:FLT3-TKD measurable residual disease in acute myeloid leukemia

| PRJNA979814 | ENA

Project description:Measurable Residual Disease in IDH mutated Acute Myeloid Leukemia patients

| PRJNA998386 | ENA

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease

Project description:The ETCTN 10026 study tested decitabine and ipilimumab for transplant-naive advanced myelodysplastic syndrome/acute myeloid leukemia and relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Using single cell RNA sequencing, determinants of response (higher T/NK to myeloid cell ratio in responders) and resistance (insufficient clearance of AML clones) were identified and pharmacodynamics of decitabine (cytoreduction) and ipilimumab (increase in regulatory T cells) characterized.

2023-10-31 | GSE223844 | GEO

Investigation of Measurable Residual Disease in Acute Myeloid Leukemia by DNA Methylation Patterns

Project description:Investigation of Measurable Residual Disease in Acute Myeloid Leukemia by DNA Methylation Patterns

| PRJNA699877 | ENA

Novel IDH1 Mutant Inhibitors for Treatment of Acute Myeloid Leukemia (ERRBS)

Project description:Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are driver mutations in acute myeloid leukemia (AML) and other cancers. We report the development of new allosteric inhibitors of mutant IDH1. Crystallographic and biochemical results demonstrated that compounds of this chemical series bind to an allosteric site and lock the enzyme in a catalytically inactive conformation, thereby enabling inhibition of different clinically relevant IDH1 mutants. Treatment of IDH1 mutant primary AML cells uniformly led to a decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells, in vitro and in vivo. Molecularly, treatment with the inhibitors led to a reversal of the DNA cytosine hypermethylation patterns caused by mutant IDH1 in AML patients’ cells. Our study provides proof-of-concept for the molecular and biological activity of novel allosteric inhibitors for targeting different mutant forms of IDH1 in leukemia. To obtain insight into the molecular mechanism of the novel IDH1 mutant allosteric inhibitor, primary AML cells were treated with either GSK321 IDH1 active inhibitor or Controls (DMSO or GSK990 inactive inhibitor) followed by DNA extraction for ERRBS analysis. Primary IDH1 mutant acute myeloid leukemia (AML) mononuclear (MNC) cells were treated in suspension cultures in differentiating media for 6 days with 3 microM GSK990 or GSK321 and an equal volume of DMSO, Followed ERRBS analysis after DNA extraction.

2015-09-21 | E-GEOD-72247 | biostudies-arrayexpress

Benefit of allograft in persistent mutations in NK-AML

Project description:Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing

| PRJEB32367 | ENA

Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

Project description:Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

| PRJNA947747 | ENA

Project description:Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia

| PRJNA421563 | ENA